| Full text | |
| Author(s): |
Jakob, Thilo
[1]
;
Rauber, Michele Myriam
[1]
;
Perez-Riverol, Amilcar
[1]
;
Spillner, Edzard
[2]
;
Blank, Simon
[3, 4, 5]
Total Authors: 5
|
| Affiliation: | [1] Justus Liebig Univ Giessen, Dept Dermatol & Allergol, Expt Dermatol & Allergy Res Grp, Giessen - Germany
[2] Aarhus Univ, Dept Engn Immunol Biotechnol, Aarhus - Denmark
[3] Tech Univ Munich, Ctr Allergy & Environm ZAUM, Sch Med, Munich - Germany
[4] German Res Ctr Environm Hlth, Helmholtz Ctr Munich, Munich - Germany
[5] German Ctr Lung Res DZL, Munich - Germany
Total Affiliations: 5
|
| Document type: | Review article |
| Source: | CURRENT ALLERGY AND ASTHMA REPORTS; v. 20, n. 9 JUN 16 2020. |
| Web of Science Citations: | 1 |
| Abstract | |
Purpose of Review In Hymenoptera venom allergy, the research focus has moved from whole venoms to individual allergenic molecules. Api m 10 (icarapin) has been described as a major allergen of honeybee venom (HBV) with potentially high relevance for diagnostics and therapy of venom allergy. Here, we review recent studies on Api m 10 characteristics as well as its role in component-resolved diagnostics and potential implications for venom-specific immunotherapy (VIT). Recent Findings Api m 10 is a major allergen of low abundance in HBV. It is an obviously unstable protein of unknown function that exhibits homologs in other insect species. Despite its low abundance in HBV, 35 to 72% of HBV-allergic patients show relevant sensitization to this allergen. Api m 10 is a marker allergen for HBV sensitization, which in many cases can help to identify primary sensitization to HBV and, hence, to discriminate between genuine sensitization and cross-reactivity. Moreover, Api m 10 might support personalized risk stratification in VIT, as dominant sensitization to Api m 10 has been identified as risk factor for treatment failure. This might be of particular importance since Api m 10 is strongly underrepresented in some therapeutic preparations commonly used for VIT. Although the role of Api m 10 in HBV allergy and tolerance induction during VIT is not fully understood, it certainly is a useful tool to unravel primary sensitization and individual sensitization profiles in component-resolved diagnostics (CRD). Moreover, a potential of Api m 10 to contribute to personalized treatment strategies in HBV allergy is emerging. (AU) | |
| FAPESP's process: | 17/22405-3 - IDENTIFICATION AND SYNTHESIS OF PEPTIDES CORRESPONDING TO B-CELL LINEAR EPITOPES IN ALLERGENS FROM VENOM OF SOCIAL HYMENOPTERA: DEVELOPMENT OF SUPPLIES FOR DIAGNOSIS AND IMMUNOTHERAPY OF ALLERGY |
| Grantee: | Amilcar Perez Riverol |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 16/16212-5 - Natural proteopeptides from the Brazilian fauna, flora and microbiota as potential models for the rational development of new drugs of therapeutic use: isolation, structure elucidation, chemical synthesis and functional activity assays |
| Grantee: | Mario Sergio Palma |
| Support Opportunities: | BIOTA-FAPESP Program - Thematic Grants |
| FAPESP's process: | 18/24834-1 - Synthetic B-cell linear epitopes of allergens from clinically relevant Hymenoptera for improved molecular diagnosis and immunotherapy of venom allergy |
| Grantee: | Amilcar Perez Riverol |
| Support Opportunities: | Scholarships abroad - Research Internship - Post-doctor |